Notably, a total of 45% of COVID‐19 convalescent patients took regular medications (Table S2) with 16 out of the 109 patients reporting intake of ACE‐ or angiotensin receptor (AT) blockers (candesartan, lisinopril, enalapril, ramipril, irbesartan, valsartan), that means, substances which have been shown to lead to increased ACE2 receptor expression in cardiac tissue in preclinical models previously.43 The gene discussed is ACE; the disease is COVID-19.